Retatrutide-related nausea should not be worsened by AOD-9604
A typical approach might begin with Retatrutide alone for 4 to 8 weeks, add BPC-157 during dose escalation when GI symptoms peak, introduce TB-500 after reaching maintenance Retatrutide doses, and finally add GHK-Cu when significant weight loss begins affecting skin appearance
Growth Hormone Receptor Upregulation GHR/JAK2 Pathway Research confirmed that BPC-157 dose- and time-dependently increases the expression of the growth hormone receptor (GHR) in tendon fibroblasts at both the mRNA and protein level
Safety Considerations When Combining Growth Hormone and GLP-1 Therapy Both sermorelin and tirzepatide can influence blood glucose, though through opposite mechanisms: sermorelin slightly raises fasting glucose in some patients (a known GH effect), while tirzepatide lowers glucose through enhanced insulin secretion and reduced hepatic glucose output
Our formulation is provided in a stabilized pre-mixed injection pen for SubQ administration
Are there risks associated with these therapies